Retatrutide Script

sources

Retatrutide References

Every citation used on this site, with DOIs and PubMed / PMC URLs.

Full citation list

All citations used across this site are listed below with full bibliographic details. DOIs link to the publisher record; PubMed/PMC URLs link to the indexed abstract or open-access full text where available.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Madsbad S, et al. The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert Opinion on Investigational Drugs. 2025;34(3):197-215. ↗
  8. Melson E, et al. What is the pipeline for future medications for obesity? International Journal of Obesity. 2025;49(3):433-451. ↗
  9. Caruso I, et al. Incretin-based therapies for the treatment of obesity-related diseases. npj Metabolic Health and Disease. 2024;2(1):31. ↗
  10. Deravi M, et al. The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. Journal of Pharmacy Technology. 2024;40(6):300-305. ↗
  11. Cooper ME, et al. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. Journal of Clinical Investigation. 2025;135(21):e194749. ↗
  12. Takrori E, et al. Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review. Medicina (Kaunas). 2025. ↗
  13. Cho YK, et al. Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. Clinical and Molecular Hepatology. 2026. ↗
  14. Muzurović E, et al. Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism: Clinical and Experimental. 2026. ↗